SARS-CoV-2 Nucleocapsid antibody

Catalog No. ABIN7794934

This anti-SARS-CoV-2 Nucleocapsid antibody is a Mouse Monoclonal antibody detecting SARS-CoV-2 Nucleocapsid in . Suitable for SARS Coronavirus-2 (SARS-CoV-2).

Quick Overview for SARS-CoV-2 Nucleocapsid antibody (ABIN7794934)

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Reactivity: SARS Coronavirus-2 (SARS-CoV-2)

Host: Mouse

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Nucleocapsid antibody is un-conjugated

Application: Please inquire

Clone: NP1-D4

Product Details anti-SARS-CoV-2 Nucleocapsid Antibody

Purpose: Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-D4) Purified No Carrier Protein

Specificity: Anti-SARS-CoV-2 Nucleocapsid, clone NP1-D4, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Furthermore, it is reported to bind to the RNA binding domain of the N protein. Antigen Distribution The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2. Background Coronavirus disease 2019 (COVID-19) is caused by the Coronaviridae family virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1. SARS-CoV-2 has four structural proteins encoded by its single-stranded, positive-sense RNA genome the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. The N protein is a highly conserved 46 kDa protein that shares 90 % homology with SARS-CoV3. The N protein has an N-terminal (NTD) and C-terminal domain (CTD), which bind to RNA and self-oligomerize, respectively4,5, forming a helical nucleocapsid structure within the viral envelope6. Other functions of the N protein included viral transcription, replication, and modulating cell signaling pathways7,8. The N protein is abundantly expressed during infection, and antibodies3,9 and memory T cells10,11 targeting the N protein have been identified in convalescent sera. Therefore, the N protein is a target in some vaccines and diagnostic assays12. The N protein also has therapeutic potential, as it evades RNAi-mediated antiviral responses13.

Purification: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Purity: >=90 % monomer by analytical SEC and SDS-Page

Isotype: IgG1

Application Details

Restrictions: For Research Use only

Handling

Concentration: 1 μg/mL

Buffer: This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Preservative: Without preservative

Storage: 4 °C,-80 °C

Storage Comment: This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at <= -70°C.Avoid Repeated Freeze Thaw Cycles.

Target Details for SARS-CoV-2 Nucleocapsid

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Alternative Name: SARS-CoV-2 Nucleocapsid (N)

Target Type: Viral Protein

Background: COV2-NP1-D4, SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein,